


## Claims

## 1. Compounds of the general Formula



Wherein


A represents an optionally substituted 5- or 6-membered heteroaryl ring;

X is O, S or a group of Formula NR<sup>13</sup> or CR<sup>14</sup>R<sup>15</sup>;

Y is O, S or a group of Formula NR<sup>16</sup> and


Residues R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> are independently of each other H, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl, or two residues constitute part of a cycloalkyl or heterocycloalkyl, or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof;

wherein compounds of Formula (I) are excluded,



wherein  $R'$  is H, alkyl, alkenyl, aryl, or heteroaryl and  $R''$  is H, OH, alkyl, aryl or heteroaryl.

2. Compounds of Claim 1, wherein A has the following structure:



3. Compounds of Claim 1 or 2, wherein X is a  $\text{CH}_2$  group.
4. Compounds of Claim 1 to 3, wherein Y is O.
5. Compounds according to anyone of Claim 1 to 4, wherein  $R^1$  is a  $\text{C}_1\text{-C}_4$  alkyl group.
6. Compounds according to anyone of Claims 1 to 5, wherein,  $R^2$  and  $R^3$  together constitute a group of Formula  $(\text{CH}_2)_n$  wherein n is 2, 3, 4 or 5.
7. Compounds according to Claims 1 to 6, wherein  $R^4$  is H or methyl.
8. Compounds according to Claims 1 to 7, wherein  $R^5$  is H.
9. Compounds according to Claims 1 to 8, wherein  $R^6$  is  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_3\text{-C}_6$  cycloalkyl or  $\text{C}_4\text{-C}_7$  alkylcycloalkyl.
10. Compounds according to Claims 1 to 9, wherein  $R^7$  is H or methyl.
11. Compounds according to Claims 1 to 10, wherein  $R^8$  is a group of Formula  $\text{CH}_2\text{OCOR}^{17}$ , wherein  $R^{17}$  is  $\text{C}_1\text{-C}_7$  alkyl or  $\text{C}_1\text{-C}_6$  alkenyl.

12. Compounds according to Claims 1 to 11, wherein  $R^9$  is  $C_1-C_6$  alkyl.
13. Compounds according to Claims 1 to 12, wherein  $R^{10}$  is H or methyl.
14. Compounds according to Claims 1 to 13, wherein  $R^{11}$  is H or a group of Formula  $(C=O)-(C_{1-4})$  alkyl.
15. Compounds according to Claims 1 to 14, wherein  $R^{12}$  is a group of Formula  $NR^{18}R^{19}$ , wherein  $R^{18}$  is H or methyl and wherein  $R^{19}$  is aralkyl or heteroaralkyl.
16. A pharmaceutical composition containing a compound according to Claims 1 to 15 and optionally carriers and/or adjuvants.
17. Use of compounds or a pharmaceutical composition according to Claims 1 to 16 for the treatment of tumors, immune diseases, autoimmune diseases, inflammatory diseases and rheumatoid arthritis as well as surface modifications of plastic or metal implants.
18. Use of a compound or a pharmaceutical composition according to Claims 1 to 16 for the treatment of cancer diseases.

The present invention relates to novel tubulysin analogs and its use for the treatment of cancer diseases.